Plasminogen activator inhibitor 1 gene polymorphisms and mirtazapine responses in Koreans with major depression
Identifieur interne : 001033 ( Istex/Corpus ); précédent : 001032; suivant : 001034Plasminogen activator inhibitor 1 gene polymorphisms and mirtazapine responses in Koreans with major depression
Auteurs : Hun Soo Chang ; Hwa-Young Lee ; Byung-Joo Ham ; Rhee-Hun Kang ; Yoo-Jung Jeong ; Hyang-Mi Kim ; Sang-Woo Hahn ; Min-Soo LeeSource :
- Asia‐Pacific Psychiatry [ 1758-5864 ] ; 2009-12.
English descriptors
- KwdEn :
Abstract
Introduction: Brain‐derived neurotrophic factor (BDNF) is involved in the pathophysiology of mental disorders and in the mechanism of action of antidepressant medications. The mature form of BDNF is derived from proBDNF through tissue type plasminogen activator (tPA) and the plasminogen system in the brain, which is regulated by an endogenous inhibitor, plasminogen activator inhibitor (PAI). Therefore, PAI may be involved in the development of major depressive disorder (MDD) and its response to antidepressant treatment. The present study determined the relationship between the 4G/5G polymorphism in the PAI1 gene and the clinical outcome of mirtazapine treatment in 271 Korean MDD patients.
Url:
DOI: 10.1111/j.1758-5872.2009.00025.x
Links to Exploration step
ISTEX:B5A66597C62E7E7687E6D16F6F7439D672D37C50Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Plasminogen activator inhibitor 1 gene polymorphisms and mirtazapine responses in Koreans with major depression</title><author><name sortKey="Chang, Hun Soo" sort="Chang, Hun Soo" uniqKey="Chang H" first="Hun Soo" last="Chang">Hun Soo Chang</name><affiliation><mods:affiliation>Department of Psychiatry, College of Medicine, Korea University, Seoul, Korea</mods:affiliation></affiliation><affiliation><mods:affiliation>Pharmacogenomic Research Center for Psychotropic Drugs, Korea University, Seoul, Korea</mods:affiliation></affiliation></author><author><name sortKey="Lee, Hwa Oung" sort="Lee, Hwa Oung" uniqKey="Lee H" first="Hwa-Young" last="Lee">Hwa-Young Lee</name><affiliation><mods:affiliation>Department of Psychiatry, College of Medicine, Korea University, Seoul, Korea</mods:affiliation></affiliation><affiliation><mods:affiliation>Pharmacogenomic Research Center for Psychotropic Drugs, Korea University, Seoul, Korea</mods:affiliation></affiliation></author><author><name sortKey="Ham, Byung Oo" sort="Ham, Byung Oo" uniqKey="Ham B" first="Byung-Joo" last="Ham">Byung-Joo Ham</name><affiliation><mods:affiliation>Department of Psychiatry, College of Medicine, Korea University, Seoul, Korea</mods:affiliation></affiliation></author><author><name sortKey="Kang, Rhee Un" sort="Kang, Rhee Un" uniqKey="Kang R" first="Rhee-Hun" last="Kang">Rhee-Hun Kang</name><affiliation><mods:affiliation>Department of Psychiatry, College of Medicine, Korea University, Seoul, Korea</mods:affiliation></affiliation><affiliation><mods:affiliation>Pharmacogenomic Research Center for Psychotropic Drugs, Korea University, Seoul, Korea</mods:affiliation></affiliation></author><author><name sortKey="Jeong, Yoo Ung" sort="Jeong, Yoo Ung" uniqKey="Jeong Y" first="Yoo-Jung" last="Jeong">Yoo-Jung Jeong</name><affiliation><mods:affiliation>Department of Psychiatry, College of Medicine, Korea University, Seoul, Korea</mods:affiliation></affiliation><affiliation><mods:affiliation>Pharmacogenomic Research Center for Psychotropic Drugs, Korea University, Seoul, Korea</mods:affiliation></affiliation></author><author><name sortKey="Kim, Hyang I" sort="Kim, Hyang I" uniqKey="Kim H" first="Hyang-Mi" last="Kim">Hyang-Mi Kim</name><affiliation><mods:affiliation>Department of Psychiatry, College of Medicine, Korea University, Seoul, Korea</mods:affiliation></affiliation><affiliation><mods:affiliation>Pharmacogenomic Research Center for Psychotropic Drugs, Korea University, Seoul, Korea</mods:affiliation></affiliation></author><author><name sortKey="Hahn, Sang Oo" sort="Hahn, Sang Oo" uniqKey="Hahn S" first="Sang-Woo" last="Hahn">Sang-Woo Hahn</name><affiliation><mods:affiliation>Department of Psychiatry, College of Medicine, Soonchunhyang University, Seoul, Korea</mods:affiliation></affiliation></author><author><name sortKey="Lee, Min Oo" sort="Lee, Min Oo" uniqKey="Lee M" first="Min-Soo" last="Lee">Min-Soo Lee</name><affiliation><mods:affiliation>Department of Psychiatry, College of Medicine, Korea University, Seoul, Korea</mods:affiliation></affiliation><affiliation><mods:affiliation>Pharmacogenomic Research Center for Psychotropic Drugs, Korea University, Seoul, Korea</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:B5A66597C62E7E7687E6D16F6F7439D672D37C50</idno><date when="2009" year="2009">2009</date><idno type="doi">10.1111/j.1758-5872.2009.00025.x</idno><idno type="url">https://api.istex.fr/document/B5A66597C62E7E7687E6D16F6F7439D672D37C50/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001033</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001033</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Plasminogen activator inhibitor 1 gene polymorphisms and mirtazapine responses in Koreans with major depression</title><author><name sortKey="Chang, Hun Soo" sort="Chang, Hun Soo" uniqKey="Chang H" first="Hun Soo" last="Chang">Hun Soo Chang</name><affiliation><mods:affiliation>Department of Psychiatry, College of Medicine, Korea University, Seoul, Korea</mods:affiliation></affiliation><affiliation><mods:affiliation>Pharmacogenomic Research Center for Psychotropic Drugs, Korea University, Seoul, Korea</mods:affiliation></affiliation></author><author><name sortKey="Lee, Hwa Oung" sort="Lee, Hwa Oung" uniqKey="Lee H" first="Hwa-Young" last="Lee">Hwa-Young Lee</name><affiliation><mods:affiliation>Department of Psychiatry, College of Medicine, Korea University, Seoul, Korea</mods:affiliation></affiliation><affiliation><mods:affiliation>Pharmacogenomic Research Center for Psychotropic Drugs, Korea University, Seoul, Korea</mods:affiliation></affiliation></author><author><name sortKey="Ham, Byung Oo" sort="Ham, Byung Oo" uniqKey="Ham B" first="Byung-Joo" last="Ham">Byung-Joo Ham</name><affiliation><mods:affiliation>Department of Psychiatry, College of Medicine, Korea University, Seoul, Korea</mods:affiliation></affiliation></author><author><name sortKey="Kang, Rhee Un" sort="Kang, Rhee Un" uniqKey="Kang R" first="Rhee-Hun" last="Kang">Rhee-Hun Kang</name><affiliation><mods:affiliation>Department of Psychiatry, College of Medicine, Korea University, Seoul, Korea</mods:affiliation></affiliation><affiliation><mods:affiliation>Pharmacogenomic Research Center for Psychotropic Drugs, Korea University, Seoul, Korea</mods:affiliation></affiliation></author><author><name sortKey="Jeong, Yoo Ung" sort="Jeong, Yoo Ung" uniqKey="Jeong Y" first="Yoo-Jung" last="Jeong">Yoo-Jung Jeong</name><affiliation><mods:affiliation>Department of Psychiatry, College of Medicine, Korea University, Seoul, Korea</mods:affiliation></affiliation><affiliation><mods:affiliation>Pharmacogenomic Research Center for Psychotropic Drugs, Korea University, Seoul, Korea</mods:affiliation></affiliation></author><author><name sortKey="Kim, Hyang I" sort="Kim, Hyang I" uniqKey="Kim H" first="Hyang-Mi" last="Kim">Hyang-Mi Kim</name><affiliation><mods:affiliation>Department of Psychiatry, College of Medicine, Korea University, Seoul, Korea</mods:affiliation></affiliation><affiliation><mods:affiliation>Pharmacogenomic Research Center for Psychotropic Drugs, Korea University, Seoul, Korea</mods:affiliation></affiliation></author><author><name sortKey="Hahn, Sang Oo" sort="Hahn, Sang Oo" uniqKey="Hahn S" first="Sang-Woo" last="Hahn">Sang-Woo Hahn</name><affiliation><mods:affiliation>Department of Psychiatry, College of Medicine, Soonchunhyang University, Seoul, Korea</mods:affiliation></affiliation></author><author><name sortKey="Lee, Min Oo" sort="Lee, Min Oo" uniqKey="Lee M" first="Min-Soo" last="Lee">Min-Soo Lee</name><affiliation><mods:affiliation>Department of Psychiatry, College of Medicine, Korea University, Seoul, Korea</mods:affiliation></affiliation><affiliation><mods:affiliation>Pharmacogenomic Research Center for Psychotropic Drugs, Korea University, Seoul, Korea</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Asia‐Pacific Psychiatry</title><idno type="ISSN">1758-5864</idno><idno type="eISSN">1758-5872</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2009-12">2009-12</date><biblScope unit="volume">1</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="143">143</biblScope><biblScope unit="page" to="151">151</biblScope></imprint><idno type="ISSN">1758-5864</idno></series><idno type="istex">B5A66597C62E7E7687E6D16F6F7439D672D37C50</idno><idno type="DOI">10.1111/j.1758-5872.2009.00025.x</idno><idno type="ArticleID">APPY25</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1758-5864</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>gene polymorphism</term><term>major depression</term><term>mirtazapine</term><term>plasminogen activator inhibitor 1</term><term>treatment response</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract">Introduction: Brain‐derived neurotrophic factor (BDNF) is involved in the pathophysiology of mental disorders and in the mechanism of action of antidepressant medications. The mature form of BDNF is derived from proBDNF through tissue type plasminogen activator (tPA) and the plasminogen system in the brain, which is regulated by an endogenous inhibitor, plasminogen activator inhibitor (PAI). Therefore, PAI may be involved in the development of major depressive disorder (MDD) and its response to antidepressant treatment. The present study determined the relationship between the 4G/5G polymorphism in the PAI1 gene and the clinical outcome of mirtazapine treatment in 271 Korean MDD patients.</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Hun Soo Chang PhD</name><affiliations><json:string>Department of Psychiatry, College of Medicine, Korea University, Seoul, Korea</json:string><json:string>Pharmacogenomic Research Center for Psychotropic Drugs, Korea University, Seoul, Korea</json:string></affiliations></json:item><json:item><name>Hwa‐Young Lee MD</name><affiliations><json:string>Department of Psychiatry, College of Medicine, Korea University, Seoul, Korea</json:string><json:string>Pharmacogenomic Research Center for Psychotropic Drugs, Korea University, Seoul, Korea</json:string></affiliations></json:item><json:item><name>Byung‐Joo Ham MD, PhD</name><affiliations><json:string>Department of Psychiatry, College of Medicine, Korea University, Seoul, Korea</json:string></affiliations></json:item><json:item><name>Rhee‐Hun Kang MD</name><affiliations><json:string>Department of Psychiatry, College of Medicine, Korea University, Seoul, Korea</json:string><json:string>Pharmacogenomic Research Center for Psychotropic Drugs, Korea University, Seoul, Korea</json:string></affiliations></json:item><json:item><name>Yoo‐Jung Jeong MS</name><affiliations><json:string>Department of Psychiatry, College of Medicine, Korea University, Seoul, Korea</json:string><json:string>Pharmacogenomic Research Center for Psychotropic Drugs, Korea University, Seoul, Korea</json:string></affiliations></json:item><json:item><name>Hyang‐Mi Kim MS</name><affiliations><json:string>Department of Psychiatry, College of Medicine, Korea University, Seoul, Korea</json:string><json:string>Pharmacogenomic Research Center for Psychotropic Drugs, Korea University, Seoul, Korea</json:string></affiliations></json:item><json:item><name>Sang‐Woo Hahn MD, PhD</name><affiliations><json:string>Department of Psychiatry, College of Medicine, Soonchunhyang University, Seoul, Korea</json:string></affiliations></json:item><json:item><name>Min‐Soo Lee MD, PhD</name><affiliations><json:string>Department of Psychiatry, College of Medicine, Korea University, Seoul, Korea</json:string><json:string>Pharmacogenomic Research Center for Psychotropic Drugs, Korea University, Seoul, Korea</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>gene polymorphism</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>major depression</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>mirtazapine</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>plasminogen activator inhibitor 1</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>treatment response</value></json:item></subject><articleId><json:string>APPY25</json:string></articleId><language><json:string>eng</json:string></language><originalGenre><json:string>article</json:string></originalGenre><qualityIndicators><score>5.765</score><pdfVersion>1.3</pdfVersion><pdfPageSize>595.276 x 782.362 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>697</abstractCharCount><pdfWordCount>4565</pdfWordCount><pdfCharCount>30102</pdfCharCount><pdfPageCount>9</pdfPageCount><abstractWordCount>100</abstractWordCount></qualityIndicators><title>Plasminogen activator inhibitor 1 gene polymorphisms and mirtazapine responses in Koreans with major depression</title><refBibs><json:item><author><json:item><name>CA Altar</name></json:item></author><host><volume>20</volume><pages><last>61</last><first>59</first></pages><author></author><title>Trends Pharmacol Sci</title></host><title>Neurotrophins and depression</title></json:item><json:item><author><json:item><name>EE Benarroch</name></json:item></author><host><volume>69</volume><pages><last>802</last><first>799</first></pages><author></author><title>beyond thrombolysis</title></host><title>Tissue plasminogen activator</title></json:item><json:item><host><author></author><title>Buchner A, Faul F, Erdfelder E (1996) G Power: A Priori, Post‐Hoc, and Compromise Power Analyses for the Macintosh (Version 2.1.1). Trier: University of Trier.</title></host></json:item><json:item><author><json:item><name>P Carmeliet</name></json:item><json:item><name>L Schoonjans</name></json:item><json:item><name>L Kieckens</name></json:item></author><host><volume>368</volume><pages><last>424</last><first>419</first></pages><author></author><title>Nature</title></host><title>Physiological consequences of loss of plasminogen activator gene function in mice</title></json:item><json:item><author><json:item><name>ZY Chen</name></json:item><json:item><name>PD Patel</name></json:item><json:item><name>G Sant</name></json:item></author><host><volume>24</volume><pages><last>4411</last><first>4401</first></pages><author></author><title>J Neurosci</title></host><title>Variant brain‐derived neurotrophic factor (BDNF) (Met66) alters the intracellular trafficking and activity‐dependent secretion of wild‐type BDNF in neurosecretory cells and cortical neurons</title></json:item><json:item><author><json:item><name>MJ Choi</name></json:item><json:item><name>RH Kang</name></json:item><json:item><name>SW Lim</name></json:item><json:item><name>KS Oh</name></json:item><json:item><name>MS Lee</name></json:item></author><host><volume>1118</volume><pages><last>182</last><first>176</first></pages><author></author><title>Brain Res</title></host><title>Brain‐derived neurotrophic factor gene polymorphism (Val66Met) and citalopram response in major depressive disorder</title></json:item><json:item><author><json:item><name>D Collen</name></json:item></author><host><volume>82</volume><pages><last>270</last><first>259</first></pages><author></author><title>Thromb Haemost</title></host><title>The plasminogen (fibrinolytic) system</title></json:item><json:item><author><json:item><name>D Collen</name></json:item></author><host><volume>2001</volume><pages><last>9</last><first>1</first></pages><author></author><title>role of the plasminogen system in fibrin-homeostasis and tissue remodeling</title></host><title>Ham‐Wasserman lecture</title></json:item><json:item><author><json:item><name>JT Coyle</name></json:item><json:item><name>RS Duman</name></json:item></author><host><volume>38</volume><pages><last>160</last><first>157</first></pages><author></author><title>Neuron</title></host><title>Finding the intracellular signaling pathways affected by mood disorder treatments</title></json:item><json:item><author><json:item><name>SJ Dawson</name></json:item><json:item><name>B Wiman</name></json:item><json:item><name>A Hamsten</name></json:item><json:item><name>F Green</name></json:item><json:item><name>S Humphries</name></json:item><json:item><name>AM Henney</name></json:item></author><host><volume>268</volume><pages><last>10745</last><first>10739</first></pages><author></author><title>J Biol Chem</title></host><title>The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor‐1 (PAI‐1) gene respond differently to interleukin‐1 in HepG2 cells</title></json:item><json:item><author><json:item><name>T De Boer</name></json:item><json:item><name>GSF Ruigt</name></json:item><json:item><name>HHG Berendsen</name></json:item></author><host><volume>10</volume><pages><last>118</last><first>107</first></pages><author></author><title>Hum Psychopharmacol</title></host><title>The alpha2‐selective adrenoceptor antagonist org 3770 (mirtazapine, Remeron®) enhances noradrenergic and serotonergic transmission</title></json:item><json:item><author><json:item><name>PL Delgado</name></json:item><json:item><name>HL Miller</name></json:item><json:item><name>RM Salomon</name></json:item></author><host><volume>29</volume><pages><last>396</last><first>389</first></pages><author></author><title>effects of catecholamine depletion on mood of patients treated with antidepressants</title></host><title>Monoamines and the mechanism of antidepressant action</title></json:item><json:item><author><json:item><name>C De Montigny</name></json:item><json:item><name>N Haddjeri</name></json:item><json:item><name>R Mongeau</name></json:item><json:item><name>P Blier</name></json:item></author><host><volume>4</volume><pages><last>17</last><first>13</first></pages><author></author><title>CNS Drugs</title></host><title>The effects of mirtazapine on the interactions between central noradrenergic and serotonergic systems</title></json:item><json:item><author><json:item><name>RS Duman</name></json:item></author><host><volume>7</volume><pages><last>34</last><first>29</first></pages><author></author><title>Mol Psychiatry</title></host><title>Synaptic plasticity and mood disorders</title></json:item><json:item><author><json:item><name>P Eriksson</name></json:item><json:item><name>B Kallin</name></json:item><json:item><name>FM Van T'hooft</name></json:item><json:item><name>P Bavhenolm</name></json:item><json:item><name>A Hamsten</name></json:item></author><host><volume>92</volume><pages><last>1855</last><first>1851</first></pages><author></author><title>Proc Natl Acad Sci</title></host><title>Allelic‐specific increase in basal transcription of the plasminogen‐activator inhibitor 1 gene is associated with myocardial infarction</title></json:item><json:item><author><json:item><name>F Eskandari</name></json:item><json:item><name>S Mistry</name></json:item><json:item><name>PE Martinez</name></json:item></author><host><volume>54</volume><pages><last>924</last><first>918</first></pages><author></author><title>implications for greater cardiovascular risk</title></host><title>Younger, premenopausal women with major depressive disorder have more abdominal fat and increased serum levels of prothrombotic factors</title></json:item><json:item><author><json:item><name>J Fawcett</name></json:item><json:item><name>RL Barkin</name></json:item></author><host><volume>51</volume><pages><last>285</last><first>267</first></pages><author></author><title>J Affect Disord</title></host><title>Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression</title></json:item><json:item><author><json:item><name>E Frank</name></json:item><json:item><name>RF Prien</name></json:item><json:item><name>RB Jarrett</name></json:item></author><host><volume>48</volume><pages><last>855</last><first>851</first></pages><author></author><title>Arch Gen Psychiatry</title></host><title>Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence</title></json:item><json:item><author><json:item><name>N Gervasoni</name></json:item><json:item><name>JM Aubry</name></json:item><json:item><name>G Bondolfi</name></json:item></author><host><volume>51</volume><pages><last>238</last><first>234</first></pages><author></author><title>Neuropsychobiology</title></host><title>Partial normalization of serum brain‐derived neurotrophic factor in remitted patients after a major depressive episode</title></json:item><json:item><author><json:item><name>D Ginsburg</name></json:item><json:item><name>R Zeheb</name></json:item><json:item><name>A Yang</name></json:item></author><host><volume>78</volume><pages><last>1680</last><first>1673</first></pages><author></author><title>J Clin Invest</title></host><title>cDNA cloning of human plasminogen activator‐inhibitor from endothelial cells</title></json:item><json:item><author><json:item><name>P Gorwood</name></json:item></author><host><author></author><title>Handbook of Molecular‐Genetic Techniques for Brain and Behavior Research</title></host><title>Genetic association studies in behavioral neuroscience</title></json:item><json:item><author><json:item><name>N Haddjeri</name></json:item><json:item><name>P Blier</name></json:item><json:item><name>C De Montigny</name></json:item></author><host><volume>10</volume><pages><last>17</last><first>11</first></pages><author></author><title>acute and long-term actions of mirtazapine</title></host><title>Noradrenergic modulation of central serotonergic neurotransmission</title></json:item><json:item><host><author></author><title>Kim JW (2003) Association Study and the Population Admixture. Human Neurobehavioral Genetics in the 21st Century. Seoul, Korea: Korean Society of Biological Psychiatry.</title></host></json:item><json:item><author><json:item><name>K Lahlou‐Laforet</name></json:item><json:item><name>M Alhenc‐Gelas</name></json:item><json:item><name>M Pornin</name></json:item></author><host><volume>97</volume><pages><last>1291</last><first>1287</first></pages><author></author><title>Am J Cardiol</title></host><title>Relation of depressive mood to plasminogen activator inhibitor, tissue plasminogen activator, and fibrinogen levels in patients with versus without coronary heart disease</title></json:item><json:item><author><json:item><name>R Lee</name></json:item><json:item><name>P Kermani</name></json:item><json:item><name>KK Teng</name></json:item><json:item><name>BL Hempstead</name></json:item></author><host><volume>294</volume><pages><last>1948</last><first>1945</first></pages><author></author><title>Science</title></host><title>Regulation of cell survival by secreted proneurotrophins</title></json:item><json:item><author><json:item><name>K Martinowich</name></json:item><json:item><name>B Lu</name></json:item></author><host><volume>33</volume><pages><last>83</last><first>73</first></pages><author></author><title>role in mood disorders</title></host><title>Interaction between BDNF and serotonin</title></json:item><json:item><author><json:item><name>JP Melchor</name></json:item><json:item><name>S Strickland</name></json:item></author><host><volume>93</volume><pages><last>660</last><first>655</first></pages><author></author><title>Thromb Haemost</title></host><title>Tissue plasminogen activator in central nervous system physiology and pathology</title></json:item><json:item><author><json:item><name>SJ Mowla</name></json:item><json:item><name>HF Farhadi</name></json:item><json:item><name>S Pareek</name></json:item></author><host><volume>276</volume><pages><last>12666</last><first>12660</first></pages><author></author><title>J Biol Chem</title></host><title>Biosynthesis and post‐translational processing of the precursor to brain‐derived neurotrophic factor</title></json:item><json:item><author><json:item><name>T Nagai</name></json:item><json:item><name>K Yamada</name></json:item><json:item><name>M Yoshimura</name></json:item></author><host><volume>101</volume><pages><last>3655</last><first>3650</first></pages><author></author><title>Proc Natl Acad Sci USA</title></host><title>The tissue plasminogen activator‐plasmin system participates in the rewarding effect of morphine by regulating dopamine release</title></json:item><json:item><author><json:item><name>EJ Nestler</name></json:item><json:item><name>E Gould</name></json:item><json:item><name>H Manji</name></json:item></author><host><volume>52</volume><pages><last>528</last><first>503</first></pages><author></author><title>status of basic research in depression</title></host><title>Preclinical models</title></json:item><json:item><author><json:item><name>DJ Nutt</name></json:item></author><host><volume>17</volume><pages><last>41</last><first>37</first></pages><author></author><title>Hum Psychopharmacol</title></host><title>Tolerability and safety aspects of mirtazapine</title></json:item><json:item><author><json:item><name>PT Pang</name></json:item><json:item><name>HK Teng</name></json:item><json:item><name>E Zaitsev</name></json:item></author><host><volume>306</volume><pages><last>491</last><first>487</first></pages><author></author><title>Science</title></host><title>Cleavage of proBDNF by tPA/plasmin is essential for long‐term hippocampal plasticity</title></json:item><json:item><author><json:item><name>SM Rodrigues</name></json:item><json:item><name>GE Schafe</name></json:item><json:item><name>JE Ledoux</name></json:item></author><host><volume>44</volume><pages><last>91</last><first>75</first></pages><author></author><title>Neuron</title></host><title>Molecular mechanisms underlying emotional learning and memory in the lateral amygdala</title></json:item><json:item><author><json:item><name>KJ Rothman</name></json:item></author><host><volume>1</volume><pages><last>46</last><first>43</first></pages><author></author><title>Epidemiology</title></host><title>No adjustments are needed for multiple comparisons</title></json:item><json:item><author><json:item><name>NG Seidah</name></json:item><json:item><name>S Benjannet</name></json:item><json:item><name>S Pareek</name></json:item></author><host><volume>314</volume><pages><last>960</last><first>951</first></pages><author></author><title>Biochem J</title></host><title>Cellular processing of the nerve growth factor precursor by the mammalian pro‐protein convertases</title></json:item><json:item><author><json:item><name>S Sen</name></json:item><json:item><name>RM Nesse</name></json:item><json:item><name>SF Stoltenberg</name></json:item></author><host><volume>28</volume><pages><last>401</last><first>397</first></pages><author></author><title>Neuropsychopharmacology</title></host><title>A BDNF coding variant is associated with the NEO personality inventory domain neuroticism, a risk factor for depression</title></json:item><json:item><author><json:item><name>A Serretti</name></json:item><json:item><name>C Lorenzi</name></json:item><json:item><name>C Cusin</name></json:item></author><host><volume>13</volume><pages><last>122</last><first>117</first></pages><author></author><title>Eur Neuropsychopharmacol</title></host><title>SSRIs antidepressant activity is influenced by G beta 3 variants</title></json:item><json:item><author><json:item><name>T Teesalu</name></json:item><json:item><name>A Kulla</name></json:item><json:item><name>A Simisker</name></json:item></author><host><volume>92</volume><pages><last>368</last><first>358</first></pages><author></author><title>Thromb Haemost</title></host><title>Tissue plasminogen activator and neuroserpin are widely expressed in the human central nervous system</title></json:item><json:item><author><json:item><name>SJ Tsai</name></json:item><json:item><name>CJ Hong</name></json:item><json:item><name>YJ Liou</name></json:item><json:item><name>YW Yu</name></json:item><json:item><name>TJ Chen</name></json:item></author><host><volume>18</volume><pages><last>875</last><first>869</first></pages><author></author><title>Pharmacogenet Genom</title></host><title>Plasminogen activator inhibitor‐1 gene is associated with major depression and antidepressant treatment response</title></json:item><json:item><author><json:item><name>HM Van Praag</name></json:item><json:item><name>GM Asnis</name></json:item><json:item><name>RS Kahn</name></json:item></author><host><volume>157</volume><pages><last>734</last><first>723</first></pages><author></author><title>Br J Psychiatry</title></host><title>Monoamines and abnormal behaviour. A multi‐aminergic perspective</title></json:item><json:item><author><json:item><name>R Ventimiglia</name></json:item><json:item><name>PE Mather</name></json:item><json:item><name>BE Jones</name></json:item><json:item><name>RM Lindsay</name></json:item></author><host><volume>7</volume><pages><last>222</last><first>213</first></pages><author></author><title>Eur J Neurosci</title></host><title>The neurotrophins BDNF, NT‐3 and NT‐4/5 promote survival and morphological and biochemical differentiation of striatal neurons in vitro</title></json:item><json:item><author><json:item><name>M Yepes</name></json:item><json:item><name>DA Lawrence</name></json:item></author><host><volume>229</volume><pages><last>1104</last><first>1097</first></pages><author></author><title>nonhemostatic roles for tissue-type plasminogen activator in the central nervous system</title></host><title>New functions for an old enzyme</title></json:item></refBibs><genre><json:string>article</json:string></genre><host><volume>1</volume><publisherId><json:string>APPY</json:string></publisherId><pages><total>9</total><last>151</last><first>143</first></pages><issn><json:string>1758-5864</json:string></issn><issue>3</issue><genre><json:string>journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1758-5872</json:string></eissn><title>Asia‐Pacific Psychiatry</title><doi><json:string>10.1111/(ISSN)1758-5872</json:string></doi></host><categories><wos><json:string>social science</json:string><json:string>psychiatry</json:string></wos><scienceMetrix></scienceMetrix></categories><publicationDate>2009</publicationDate><copyrightDate>2009</copyrightDate><doi><json:string>10.1111/j.1758-5872.2009.00025.x</json:string></doi><id>B5A66597C62E7E7687E6D16F6F7439D672D37C50</id><score>0.119418316</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/document/B5A66597C62E7E7687E6D16F6F7439D672D37C50/fulltext/pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/document/B5A66597C62E7E7687E6D16F6F7439D672D37C50/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/B5A66597C62E7E7687E6D16F6F7439D672D37C50/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Plasminogen activator inhibitor 1 gene polymorphisms and mirtazapine responses in Koreans with major depression</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><availability><p>© 2009 Blackwell Publishing Asia Pty Ltd</p></availability><date>2009</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Plasminogen activator inhibitor 1 gene polymorphisms and mirtazapine responses in Koreans with major depression</title><author xml:id="author-1"><persName><forename type="first">Hun Soo</forename><surname>Chang</surname></persName><roleName type="degree">PhD</roleName><affiliation>Department of Psychiatry, College of Medicine, Korea University, Seoul, Korea</affiliation><affiliation>Pharmacogenomic Research Center for Psychotropic Drugs, Korea University, Seoul, Korea</affiliation></author><author xml:id="author-2"><persName><forename type="first">Hwa‐Young</forename><surname>Lee</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Psychiatry, College of Medicine, Korea University, Seoul, Korea</affiliation><affiliation>Pharmacogenomic Research Center for Psychotropic Drugs, Korea University, Seoul, Korea</affiliation></author><author xml:id="author-3"><persName><forename type="first">Byung‐Joo</forename><surname>Ham</surname></persName><roleName type="degree">MD, PhD</roleName><affiliation>Department of Psychiatry, College of Medicine, Korea University, Seoul, Korea</affiliation></author><author xml:id="author-4"><persName><forename type="first">Rhee‐Hun</forename><surname>Kang</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Psychiatry, College of Medicine, Korea University, Seoul, Korea</affiliation><affiliation>Pharmacogenomic Research Center for Psychotropic Drugs, Korea University, Seoul, Korea</affiliation></author><author xml:id="author-5"><persName><forename type="first">Yoo‐Jung</forename><surname>Jeong</surname></persName><roleName type="degree">MS</roleName><affiliation>Department of Psychiatry, College of Medicine, Korea University, Seoul, Korea</affiliation><affiliation>Pharmacogenomic Research Center for Psychotropic Drugs, Korea University, Seoul, Korea</affiliation></author><author xml:id="author-6"><persName><forename type="first">Hyang‐Mi</forename><surname>Kim</surname></persName><roleName type="degree">MS</roleName><affiliation>Department of Psychiatry, College of Medicine, Korea University, Seoul, Korea</affiliation><affiliation>Pharmacogenomic Research Center for Psychotropic Drugs, Korea University, Seoul, Korea</affiliation></author><author xml:id="author-7"><persName><forename type="first">Sang‐Woo</forename><surname>Hahn</surname></persName><roleName type="degree">MD, PhD</roleName><affiliation>Department of Psychiatry, College of Medicine, Soonchunhyang University, Seoul, Korea</affiliation></author><author xml:id="author-8"><persName><forename type="first">Min‐Soo</forename><surname>Lee</surname></persName><roleName type="degree">MD, PhD</roleName><affiliation>Department of Psychiatry, College of Medicine, Korea University, Seoul, Korea</affiliation><affiliation>Pharmacogenomic Research Center for Psychotropic Drugs, Korea University, Seoul, Korea</affiliation></author></analytic><monogr><title level="j">Asia‐Pacific Psychiatry</title><idno type="pISSN">1758-5864</idno><idno type="eISSN">1758-5872</idno><idno type="DOI">10.1111/(ISSN)1758-5872</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2009-12"></date><biblScope unit="volume">1</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="143">143</biblScope><biblScope unit="page" to="151">151</biblScope></imprint></monogr><idno type="istex">B5A66597C62E7E7687E6D16F6F7439D672D37C50</idno><idno type="DOI">10.1111/j.1758-5872.2009.00025.x</idno><idno type="ArticleID">APPY25</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2009</date></creation><langUsage><language ident="en">en</language></langUsage><abstract><p>Introduction: Brain‐derived neurotrophic factor (BDNF) is involved in the pathophysiology of mental disorders and in the mechanism of action of antidepressant medications. The mature form of BDNF is derived from proBDNF through tissue type plasminogen activator (tPA) and the plasminogen system in the brain, which is regulated by an endogenous inhibitor, plasminogen activator inhibitor (PAI). Therefore, PAI may be involved in the development of major depressive disorder (MDD) and its response to antidepressant treatment. The present study determined the relationship between the 4G/5G polymorphism in the PAI1 gene and the clinical outcome of mirtazapine treatment in 271 Korean MDD patients.</p></abstract><abstract><p>Methods: We tested the association between the polymorphism and response to mirtazapine treatment or percentage decrease of the 21‐item Hamilton Depression Rating (HAMD21) scores using multiple logistic and linear regression analysis.</p></abstract><abstract><p>Results: PAI1 4G/5G genotypes and allele distributions were comparable between responders and non‐responders during the treatment period. Similarly, linear regression showed no association between genotypes or alleles and the percentage decline in total HAMD21 with mirtazapine treatment. In the analysis of symptomatic subscores, the percentage decline in the psychic anxiety and delusion scores after 4 weeks of mirtazapine treatment showed a statistical trend to a difference among genotypes, although it was not statistically significance.</p></abstract><abstract><p>Discussion: In this first pharmacogenetics study of the PAI1 4G/5G polymorphism and mirtazapine treatment response, our results do not support the hypothesis that this polymorphism is involved in the therapeutic response to mirtazapine.</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>keywords</head><item><term>gene polymorphism</term></item><item><term>major depression</term></item><item><term>mirtazapine</term></item><item><term>plasminogen activator inhibitor 1</term></item><item><term>treatment response</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2009-12">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/document/B5A66597C62E7E7687E6D16F6F7439D672D37C50/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Blackwell Publishing Ltd</publisherName><publisherLoc>Oxford, UK</publisherLoc></publisherInfo><doi origin="wiley" registered="yes">10.1111/(ISSN)1758-5872</doi><issn type="print">1758-5864</issn><issn type="electronic">1758-5872</issn><idGroup><id type="product" value="APPY"></id><id type="publisherDivision" value="ST"></id></idGroup><titleGroup><title type="main" sort="ASIA PACIFIC PSYCHIATRY">Asia‐Pacific Psychiatry</title></titleGroup></publicationMeta><publicationMeta level="part" position="12003"><doi origin="wiley">10.1111/appy.2009.1.issue-3</doi><numberingGroup><numbering type="journalVolume" number="1">1</numbering><numbering type="journalIssue" number="3">3</numbering></numberingGroup><coverDate startDate="2009-12">December 2009</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="7" status="forIssue"><doi origin="wiley">10.1111/j.1758-5872.2009.00025.x</doi><idGroup><id type="unit" value="APPY25"></id><id type="supplier" value="25"></id></idGroup><countGroup><count type="pageTotal" number="9"></count></countGroup><titleGroup><title type="tocHeading1">ORIGINAL ARTICLES</title></titleGroup><copyright>© 2009 Blackwell Publishing Asia Pty Ltd</copyright><eventGroup><event type="firstOnline" date="2009-10-27"></event><event type="publishedOnlineFinalForm" date="2009-11-30"></event><event type="xmlConverted" agent="Converter:BPG_TO_WML3G version:2.3.3 mode:FullText source:FullText result:FullText" date="2010-03-18"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-01-04"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-15"></event></eventGroup><numberingGroup><numbering type="pageFirst" number="143">143</numbering><numbering type="pageLast" number="151">151</numbering></numberingGroup><correspondenceTo>
Min‐Soo Lee MD PhD, Department of Psychiatry, Anam Hospital, Korea University College of Medicine, Anam‐dong, Seongbuk‐Gu, Seoul, Korea.
Tel: +82 2 920 5354
Fax: +82 2 923 3507 ext. 5998
Email: <email normalForm="leeminso@korea.ac.kr">leeminso@korea.ac.kr</email></correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:APPY.APPY25.pdf"></link></linkGroup></publicationMeta><contentMeta><unparsedEditorialHistory>Received: 18 March 2009Accepted 6 August 2009</unparsedEditorialHistory><countGroup><count type="figureTotal" number="0"></count><count type="tableTotal" number="5"></count><count type="formulaTotal" number="0"></count><count type="referenceTotal" number="42"></count><count type="wordTotal" number="6259"></count><count type="linksCrossRef" number="61"></count></countGroup><titleGroup><title type="main">Plasminogen activator inhibitor 1 gene polymorphisms and mirtazapine responses in Koreans with major depression</title><title type="shortAuthors">H.S. Chang <i>et al.</i></title><title type="short">PAI1 variation and mirtazapine response</title></titleGroup><creators><creator creatorRole="author" xml:id="cr1" affiliationRef="#a1 #a2"><personName><givenNames>Hun Soo</givenNames><familyName>Chang</familyName><degrees>PhD</degrees></personName></creator><creator creatorRole="author" xml:id="cr2" affiliationRef="#a1 #a2"><personName><givenNames>Hwa‐Young</givenNames><familyName>Lee</familyName><degrees>MD</degrees></personName></creator><creator creatorRole="author" xml:id="cr3" affiliationRef="#a1"><personName><givenNames>Byung‐Joo</givenNames><familyName>Ham</familyName><degrees>MD, PhD</degrees></personName></creator><creator creatorRole="author" xml:id="cr4" affiliationRef="#a1 #a2"><personName><givenNames>Rhee‐Hun</givenNames><familyName>Kang</familyName><degrees>MD</degrees></personName></creator><creator creatorRole="author" xml:id="cr5" affiliationRef="#a1 #a2"><personName><givenNames>Yoo‐Jung</givenNames><familyName>Jeong</familyName><degrees>MS</degrees></personName></creator><creator creatorRole="author" xml:id="cr6" affiliationRef="#a1 #a2"><personName><givenNames>Hyang‐Mi</givenNames><familyName>Kim</familyName><degrees>MS</degrees></personName></creator><creator creatorRole="author" xml:id="cr7" affiliationRef="#a3"><personName><givenNames>Sang‐Woo</givenNames><familyName>Hahn</familyName><degrees>MD, PhD</degrees></personName></creator><creator creatorRole="author" xml:id="cr8" affiliationRef="#a1 #a2"><personName><givenNames>Min‐Soo</givenNames><familyName>Lee</familyName><degrees>MD, PhD</degrees></personName></creator></creators><affiliationGroup><affiliation xml:id="a1" countryCode="KR"><unparsedAffiliation>Department of Psychiatry, College of Medicine, Korea University, Seoul, Korea</unparsedAffiliation></affiliation><affiliation xml:id="a2" countryCode="KR"><unparsedAffiliation>Pharmacogenomic Research Center for Psychotropic Drugs, Korea University, Seoul, Korea</unparsedAffiliation></affiliation><affiliation xml:id="a3" countryCode="KR"><unparsedAffiliation>Department of Psychiatry, College of Medicine, Soonchunhyang University, Seoul, Korea</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en"><keyword xml:id="k1">gene polymorphism</keyword><keyword xml:id="k2">major depression</keyword><keyword xml:id="k3">mirtazapine</keyword><keyword xml:id="k4">plasminogen activator inhibitor 1</keyword><keyword xml:id="k5">treatment response</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p><b>Introduction: </b> Brain‐derived neurotrophic factor (BDNF) is involved in the pathophysiology of mental disorders and in the mechanism of action of antidepressant medications. The mature form of BDNF is derived from proBDNF through tissue type plasminogen activator (tPA) and the plasminogen system in the brain, which is regulated by an endogenous inhibitor, plasminogen activator inhibitor (PAI). Therefore, PAI may be involved in the development of major depressive disorder (MDD) and its response to antidepressant treatment. The present study determined the relationship between the <i>4G/5G</i> polymorphism in the PAI1 gene and the clinical outcome of mirtazapine treatment in 271 Korean MDD patients.</p><p><b>Methods: </b> We tested the association between the polymorphism and response to mirtazapine treatment or percentage decrease of the 21‐item Hamilton Depression Rating (HAMD21) scores using multiple logistic and linear regression analysis.</p><p><b>Results: </b> <i>PAI1 4G/5G</i> genotypes and allele distributions were comparable between responders and non‐responders during the treatment period. Similarly, linear regression showed no association between genotypes or alleles and the percentage decline in total HAMD21 with mirtazapine treatment. In the analysis of symptomatic subscores, the percentage decline in the psychic anxiety and delusion scores after 4 weeks of mirtazapine treatment showed a statistical trend to a difference among genotypes, although it was not statistically significance.</p><p><b>Discussion: </b> In this first pharmacogenetics study of the <i>PAI1 4G/5G</i> polymorphism and mirtazapine treatment response, our results do not support the hypothesis that this polymorphism is involved in the therapeutic response to mirtazapine.</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Plasminogen activator inhibitor 1 gene polymorphisms and mirtazapine responses in Koreans with major depression</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>PAI1 variation and mirtazapine response</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Plasminogen activator inhibitor 1 gene polymorphisms and mirtazapine responses in Koreans with major depression</title></titleInfo><name type="personal"><namePart type="given">Hun Soo</namePart><namePart type="family">Chang</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>Department of Psychiatry, College of Medicine, Korea University, Seoul, Korea</affiliation><affiliation>Pharmacogenomic Research Center for Psychotropic Drugs, Korea University, Seoul, Korea</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Hwa‐Young</namePart><namePart type="family">Lee</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Psychiatry, College of Medicine, Korea University, Seoul, Korea</affiliation><affiliation>Pharmacogenomic Research Center for Psychotropic Drugs, Korea University, Seoul, Korea</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Byung‐Joo</namePart><namePart type="family">Ham</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Department of Psychiatry, College of Medicine, Korea University, Seoul, Korea</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Rhee‐Hun</namePart><namePart type="family">Kang</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Psychiatry, College of Medicine, Korea University, Seoul, Korea</affiliation><affiliation>Pharmacogenomic Research Center for Psychotropic Drugs, Korea University, Seoul, Korea</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Yoo‐Jung</namePart><namePart type="family">Jeong</namePart><namePart type="termsOfAddress">MS</namePart><affiliation>Department of Psychiatry, College of Medicine, Korea University, Seoul, Korea</affiliation><affiliation>Pharmacogenomic Research Center for Psychotropic Drugs, Korea University, Seoul, Korea</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Hyang‐Mi</namePart><namePart type="family">Kim</namePart><namePart type="termsOfAddress">MS</namePart><affiliation>Department of Psychiatry, College of Medicine, Korea University, Seoul, Korea</affiliation><affiliation>Pharmacogenomic Research Center for Psychotropic Drugs, Korea University, Seoul, Korea</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Sang‐Woo</namePart><namePart type="family">Hahn</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Department of Psychiatry, College of Medicine, Soonchunhyang University, Seoul, Korea</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Min‐Soo</namePart><namePart type="family">Lee</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Department of Psychiatry, College of Medicine, Korea University, Seoul, Korea</affiliation><affiliation>Pharmacogenomic Research Center for Psychotropic Drugs, Korea University, Seoul, Korea</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>Blackwell Publishing Ltd</publisher><place><placeTerm type="text">Oxford, UK</placeTerm></place><dateIssued encoding="w3cdtf">2009-12</dateIssued><edition>Received: 18 March 2009Accepted 6 August 2009</edition><copyrightDate encoding="w3cdtf">2009</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="tables">5</extent><extent unit="references">42</extent><extent unit="words">6259</extent></physicalDescription><abstract>Introduction: Brain‐derived neurotrophic factor (BDNF) is involved in the pathophysiology of mental disorders and in the mechanism of action of antidepressant medications. The mature form of BDNF is derived from proBDNF through tissue type plasminogen activator (tPA) and the plasminogen system in the brain, which is regulated by an endogenous inhibitor, plasminogen activator inhibitor (PAI). Therefore, PAI may be involved in the development of major depressive disorder (MDD) and its response to antidepressant treatment. The present study determined the relationship between the 4G/5G polymorphism in the PAI1 gene and the clinical outcome of mirtazapine treatment in 271 Korean MDD patients.</abstract><abstract>Methods: We tested the association between the polymorphism and response to mirtazapine treatment or percentage decrease of the 21‐item Hamilton Depression Rating (HAMD21) scores using multiple logistic and linear regression analysis.</abstract><abstract>Results: PAI1 4G/5G genotypes and allele distributions were comparable between responders and non‐responders during the treatment period. Similarly, linear regression showed no association between genotypes or alleles and the percentage decline in total HAMD21 with mirtazapine treatment. In the analysis of symptomatic subscores, the percentage decline in the psychic anxiety and delusion scores after 4 weeks of mirtazapine treatment showed a statistical trend to a difference among genotypes, although it was not statistically significance.</abstract><abstract>Discussion: In this first pharmacogenetics study of the PAI1 4G/5G polymorphism and mirtazapine treatment response, our results do not support the hypothesis that this polymorphism is involved in the therapeutic response to mirtazapine.</abstract><subject lang="en"><genre>keywords</genre><topic>gene polymorphism</topic><topic>major depression</topic><topic>mirtazapine</topic><topic>plasminogen activator inhibitor 1</topic><topic>treatment response</topic></subject><relatedItem type="host"><titleInfo><title>Asia‐Pacific Psychiatry</title></titleInfo><genre type="journal">journal</genre><identifier type="ISSN">1758-5864</identifier><identifier type="eISSN">1758-5872</identifier><identifier type="DOI">10.1111/(ISSN)1758-5872</identifier><identifier type="PublisherID">APPY</identifier><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>1</number></detail><detail type="issue"><caption>no.</caption><number>3</number></detail><extent unit="pages"><start>143</start><end>151</end><total>9</total></extent></part></relatedItem><identifier type="istex">B5A66597C62E7E7687E6D16F6F7439D672D37C50</identifier><identifier type="DOI">10.1111/j.1758-5872.2009.00025.x</identifier><identifier type="ArticleID">APPY25</identifier><accessCondition type="use and reproduction" contentType="copyright">© 2009 Blackwell Publishing Asia Pty Ltd</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Blackwell Publishing Ltd</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Rhénanie/explor/UnivTrevesV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001033 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 001033 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Rhénanie
|area= UnivTrevesV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:B5A66597C62E7E7687E6D16F6F7439D672D37C50
|texte= Plasminogen activator inhibitor 1 gene polymorphisms and mirtazapine responses in Koreans with major depression
}}
| This area was generated with Dilib version V0.6.31. |  |